Effect of NMES on Spasticity

Spasticity is a sensory-motor control disorder arising from upper motor neuron lesions, affecting approximately 97% of chronic stroke patients presenting with moderate-to-severe motor impairment. This pathology is driven by stretch reflex hyperexcitability, stemming from secondary alterations in the supraspinal, spinal interneuronal, and striated muscle systems; it manifests as an exaggerated reflex response to peripheral stimuli and concomitant excessive muscle activity. While several definitions exist in the literature, the operational conceptualization of spasticity as 'the enhancement of velocity-dependent stretch reflexes, measured at rest' establishes it as a highly quantifiable and robust target variable for clinical evaluation and scientific investigation.

Spasticity management encompasses diverse therapeutic modalities, ranging from pharmacological to non-pharmacological approaches. Among these, neuromuscular electrical stimulation (NMES) has emerged as a prominent intervention. Although documented as a beneficial adjunctive therapy, the clinical translation of NMES from randomized controlled trials to bedside practice is frequently hindered by marked study heterogeneity and a scarcity of high-quality evidence. Moreover, despite its clinical adoption, NMES application parameters remain largely unstandardized, and substantial inter-individual variability precludes the direct extrapolation of group-level averages to individual patients. Therefore, rigorous experimental frameworks capable of generating robust, individual-level scientific evidence are required to guide real-world practice and optimize personalized therapeutic decisions. Within this paradigm, single-subject experimental designs represent a highly promising methodological approach.

Consequently, this study investigates the therapeutic efficacy of NMES on spasticity among chronic stroke patients with spastic paresis lasting longer than one year, utilizing single-subject experimental methodologies-specifically withdrawal/reversal and multiple-baseline designs. To achieve this, this research addresses four primary objectives: evaluating whether standalone NMES reduces spasticity severity; determining the longevity of any observed therapeutic effect; quantifying the precise magnitude of this intervention; and examining the generalizability of the outcomes. Framed within the context of the experimental design-analysis paradigm, we hypothesize that isolated NMES application will significantly reduce spasticity. This hypothesis will be systematically tested across three distinct stages. The initial pilot stage will delineate the presence, magnitude, and duration of NMES efficacy using predefined stimulation parameters. Subsequently, the second stage will implement a withdrawal/reversal design with built-in wash-out periods to provide robust causal evidence regarding NMES outcomes. Finally, the third stage will deploy a multiple-baseline design across participants to establish the generalizability of the intervention parameters.

In the first stage, a basic phase-change (A-B) design will be applied to a single participant, where Phase A represents the untreated baseline period, and Phase B denotes the NMES application followed immediately by post-treatment assessments. Specifically, the participant will undergo a baseline assessment at 10-minute intervals for one hour, followed by a 20-minute NMES application, and subsequent post-treatment assessments at 10-minute intervals for two hours. This initial stage serves as a pilot phase designed to evaluate potential NMES-related effects, and progression to Stage 2 will occur independently of the treatment's efficacy status during this pilot.

In the second stage, this daily procedure is planned to be repeated over four consecutive days separated by washout intervals for the same participant, yielding a full A-B-A-B-A-B-A sequence. However, the study incorporates a strict ethical stopping rule: if visual analysis reveals no positive clinical response by the end of the second day (concluding the initial A-B-A-B phases), the protocol will be discontinued immediately due to futility, and the study will not proceed to the final stage. Conversely, if a positive response is verified visually, the full four-day sequence will be completed, and a non-concurrent multiple baseline design across participants (the final stage) will subsequently be implemented.

In the final stage, the single-day (A-B) procedure will be applied only once to three additional participants. To ensure methodological rigor, the baseline lengths for these three participants will consist of 5, 7, and 9 assessments, respectively, assigned in a randomized order.